John D Imig

List of Publications by Year in Descending Order

251 papers	9,689 citations	56 h-index	87 g-index
323 ext. papers	10,490 ext. citations	5.1 avg, IF	6.48 L-index

#	Paper	IF	Citations
251	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. *Current Opinion in Nephrology and Hypertension*, **2022**, 31, 36-46	3.5	2
250	SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection.. *Clinical Science*, **2022**, 136, 431-434	6.5	2
249	Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.. *Frontiers in Pharmacology*, **2021**, 12, 798642	5.6	1
248	Epoxylipids and soluble epoxide hydrolase in heart diseases. *Biochemical Pharmacology*, **2021**, 195, 114866		3
247	Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. *Frontiers in Immunology* , **2021**, 12, 747794	8.4	
246	Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
245	Diabetes risk associated with plasma epoxylipid levels. *EBioMedicine*, **2021**, 66, 103331	8.8	0
244	Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats. *Frontiers in Physiology*, **2021**, 12, 622882	4.6	3
243	Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. *Hypertension*, **2021**, 77, 582-593	8.5	0
242	Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation. *Biomedicines*, **2021**, 9,	4.8	1
241	Multi-Target Drugs for Kidney Diseases.. *Kidney360*, **2021**, 2, 1645-1653	1.8	0
240	Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. *British Journal of Pharmacology*, **2021**, 178, 4468-4484	8.6	2
239	Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.. *Frontiers in Pharmacology*, **2021**, 12, 744776	5.6	2
238	Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. *Hypertension*, **2020**, 76, 3-15	8.5	9
237	Dual soluble epoxide hydrolase inhibitor/PPAR-□agonist attenuates renal fibrosis. *Prostaglandins and Other Lipid Mediators*, **2020**, 150, 106472	3.7	7
236	A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE. *Bulletin of Taras Shevchenko National University of Kyiv Series Biology*, **2020**, 81, 25-31	0.2	1
235	THE EFFECT OF COMPOUND DM509 ON KIDNEY FIBROSIS IN THE CONDITIONS OF THE EXPERIMENTAL MODEL. *Bulletin of Taras Shevchenko National University of Kyiv Series Biology*, **2020** , 80, 10-15	0.2	2

234	REVERSAL OF UNILATERAL URETERAL OBSTRUCTION LEADS TO SALT-SENSITIVE HYPERTENSION. *FASEB Journal*, **2020**, 34, 1-1	0.9	
233	DUAL ACTING COX-2 AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR ATTENUATES GLOMERULAR INJURY IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS. *FASEB Journal*, **2020**, 34, 1-1	0.9	
232	Effective Antihypertensive Treatment with Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Antagonist (AAA) of Spontaneously Hypertensive Rats (SHR). *FASEB Journal*, **2020**, 34, 1-1	0.9	
231	A DUAL COX-2/sEH INHIBITOR TREATED KIDNEY INJURY IN A DRUG-INDUCED GLOMERULAR DISEASE MODEL. *FASEB Journal*, **2020**, 34, 1-1	0.9	
230	Fructose Consumption Increases Blood Pressure and Induces Changes in Renal Microvascular Function. *FASEB Journal*, **2020**, 34, 1-1	0.9	
229	COMBINED FARNESOID X RECEPTOR AGONIST AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR TREATS PROGRESSIVE RENAL FIBROSIS. *FASEB Journal*, **2020**, 34, 1-1	0.9	
228	Eicosanoid blood vessel regulation in physiological and pathological states. *Clinical Science*, **2020**, 134, 2707-2727	6.5	12
227	Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. *Journal of Hypertension*, **2020**, 38, 1802-1810	1.9	6
226	Multi-Target Approaches in Metabolic Syndrome. *Frontiers in Pharmacology*, **2020**, 11, 554961	5.6	11
225	Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. *Frontiers in Pharmacology*, **2019**, 10, 18	5.6	7
224	A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. *Biochemical Pharmacology*, **2019**, 166, 212-221	6	13
223	Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. *Frontiers in Pharmacology*, **2019**, 10, 512	5.6	9
222	Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Transgenic Rats. *Frontiers in Pharmacology*, **2019**, 10, 159	5.6	10
221	Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. *Clinical Science*, **2019**, 133, 939-951	6.5	12
220	Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart. *Scientific Reports*, **2019**, 9, 11004	4.9	8
219	Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. *Kidney and Blood Pressure Research*, **2019**, 44, 792-809	3.1	9
218	Epoxyeicosanoids in hypertension. *Physiological Research*, **2019**, 68, 695-704	2.1	18
217	Glomerular Mesangial Proliferation is Mitigated by sEH/COX-2 Dual-Inhibition. *FASEB Journal*, **2019**, 33, 671.7	0.9	

216	A Dual Farnesoid X Receptor Agonist /Soluble Epoxide Hydrolase Inhibitor Prevents Non-Alcoholic Steatohepatitis in Mice. *FASEB Journal*, **2019**, 33, 506.3	0.9	
215	EET Analogs and the Dual-Inhibition of sEH/COX-2 for the Treatment of Focal Segmental Glomerular Sclerosis. *FASEB Journal*, **2019**, 33, 863.8	0.9	
214	A Novel Dual Soluble Epoxide Hydrolase Inhibitor/Cyclooxygenase-2 Inhibitor Treats Type 2 Diabetic Complications in Obese ZSF1 Rats. *FASEB Journal*, **2019**, 33, 514.2	0.9	
213	A Dual Soluble Epoxide Hydrolase Inhibitor/PPAR-Agonist Prevents Renal Fibrosis in Mouse Unilateral Ureteral Obstruction Model. *FASEB Journal*, **2019**, 33, 678.12	0.9	1
212	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. *Kidney and Blood Pressure Research*, **2019**, 44, 1493-1505	3.1	1
211	Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. *Nephrology Dialysis Transplantation*, **2018**, 33, 1333-1343	4.3	7
210	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. *Kidney and Blood Pressure Research*, **2018**, 43, 329-349	3.1	8
209	Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. *Journal of Hypertension*, **2018**, 36, 1326-1341	1.9	19
208	Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1via downregulation of prolyl hydroxylase 3. *American Journal of Physiology - Heart and Circulatory Physiology*, **2018**, 315, H1148-H1158	5.2	12
207	A novel dual PPAR-agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. *Diabetologia*, **2018**, 61, 2235-2246	10.3	27
206	Inactivation of p66Shc Decreases Afferent Arteriolar K Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. *Diabetes*, **2018**, 67, 2206-2212	0.9	9
205	The Effect of Voltage-Sensitive Chloride Channel 6 on Development of Salt-Sensitive Hypertension. *FASEB Journal*, **2018**, 32, 750.23	0.9	
204	Molecular Pathways in Hypertensive Renal Damage. *Updates in Hypertension and Cardiovascular Protection*, **2018**, 445-463	0.1	2
203	SP074SOLUBLE EPOXIDE HYDROLASE INHIBITION AUGMENTS RAS BLOCKADE RENOPROTECTION INSUBTOTALLY NEPHRECTOMIZED REN-2 TRANSGENIC HYPERTENSIVE RATS WITH CHRONIC KIDNEY DISEASE. *Nephrology Dialysis Transplantation*, **2018**, 33, i370-i370	4.3	
202	20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. *Bioscience Reports*, **2018**, 38,	4.1	8
201	Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. *Pharmacology & Therapeutics*, **2018**, 192, 1-19	13.9	43
200	Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. *Diabetologia*, **2017**, 60, 1066-1075	10.3	24
199	Orally Active Epoxyeicosatrienoic Acid Analogs. *Journal of Cardiovascular Pharmacology*, **2017**, 70, 211-224	3.1	27

198	Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. *Biochimica Et Biophysica Acta - General Subjects*, **2017**, 1861, 2758-2765	4	19
197	Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. *Frontiers in Pharmacology*, **2017**, 8, 406	5.6	22
196	Mitigation of normal tissue radiation injury: evidence from rat radiation nephropathy models. *Journal of Radiation Oncology*, **2016**, 5, 1-8	0.7	1
195	Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 310, H1695-701	5.2	3
194	A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. *Prostaglandins and Other Lipid Mediators*, **2016**, 125, 40-7	3.7	31
193	Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. *Journal of Hypertension*, **2016**, 34, 2008-25	1.9	17
192	p66Shc regulates renal vascular tone in hypertension-induced nephropathy. *Journal of Clinical Investigation*, **2016**, 126, 2533-46	15.9	28
191	Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	20
190	The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. *American Journal of Physiology - Renal Physiology*, **2016**, 311, F576-85	4.3	14
189	Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive RatsRExhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. *American Journal of the Medical Sciences*, **2016**, 351, 513-9	2.2	7
188	Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. *Clinical Science*, **2016**, 130, 587-99	6.5	20
187	Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. *Advances in Pharmacology*, **2016**, 77, 105-41	5.7	51
186	Epoxyeicosatrienoic acids, hypertension, and kidney injury. *Hypertension*, **2015**, 65, 476-82	8.5	60
185	Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. *Purinergic Signalling*, **2015**, 11, 519-31	3.8	8
184	Tumour necrosis factor-□contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia. *Acta Physiologica*, **2015**, 214, 97-108	5.6	14
183	Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. *Vascular Pharmacology* , **2015**, 73, 45-56	5.9	11
182	Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. *Comprehensive Physiology*, **2015**, 6, 423-41	7.7	15
181	Reply to "Letter to the editor: RConcern regarding quantification of urinary nephrin by commercially available ELISAR". *American Journal of Physiology - Renal Physiology*, **2015**, 309, F271	4.3	

180	Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 597-610	12.7	35
179	Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. *American Journal of Physiology - Renal Physiology*, **2015**, 308, F131-9	4.3	47
178	Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats. *PLoS ONE*, **2015**, 10, e0145335	3.7	1
177	Radiation Nephropathy is Mitigated by Epoxyeicosatrienoic acid Analog. *FASEB Journal*, **2015**, 29, 938.4	0.9	
176	Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats. *American Journal of Hypertension*, **2014**, 27, 1087-95	2.3	12
175	14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. *Journal of Medicinal Chemistry*, **2014**, 57, 6965-72	8.3	24
174	Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. *Cardiovascular Drugs and Therapy*, **2014**, 28, 313-22	3.9	17
173	The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. *Journal of Biological Chemistry*, **2014**, 289, 4377-86	5.4	45
172	Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. *Frontiers in Pharmacology*, **2014**, 5, 216	5.6	27
171	Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. *Clinical and Experimental Pharmacology and Physiology*, **2014**, 41, 227-37	3	30
170	Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. *American Journal of Physiology - Renal Physiology*, **2014**, 307, F971-80	4.3	62
169	Fructose stimulates Na/H exchange activity and sensitizes the proximal tubule to angiotensin II. *Hypertension*, **2014**, 63, e68-73	8.5	55
168	Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. *Clinical Science*, **2014**, 127, 463-74	6.5	52
167	Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. *Clinical and Experimental Pharmacology and Physiology*, **2014**, 41, 1003-13	3	16
166	Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. *Diabetologia*, **2014**, 57, 413-23	10.3	102
165	A dual COX-sEH inhibitor improved glycemic status and reduced kidney injury in Zucker diabetic fatty rat (689.4). *FASEB Journal*, **2014**, 28, 689.4	0.9	
164	Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. *FASEB Journal*, **2013**, 27, 2946-56	0.9	59
163	Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. *Prostaglandins and Other Lipid Mediators*, **2013**, 104-105, 2-7	3.7	49

162	Immune and inflammatory role in renal disease. *Comprehensive Physiology*, **2013**, 3, 957-76	7.7	185
161	Anti-inflammatory effects of ﬂ polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. *Journal of Cardiovascular Pharmacology*, **2013**, 62, 285-97	3.1	78
160	Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. *Hypertension*, **2013**, 62, 905-13	8.5	47
159	Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. *Clinical and Experimental Pharmacology and Physiology*, **2013**, 40, 273-81	3	17
158	Afferent Arteriolar Responses to ﬂmethylene ATP and 20-HETE are not Blocked by ENaC Inhibition. *Physiological Reports*, **2013**, 1, e00082	2.6	7
157	Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. *Journal of Hypertension*, **2013**, 31, 321-32	1.9	18
156	A novel epoxyeicosatrienoic acid analog attenuates hypertension and renal injury in Cyp2c44 KO mice. *FASEB Journal*, **2013**, 27, 880.1	0.9	
155	Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 454-61	3	18
154	Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. *Clinical Science*, **2012**, 122, 513-25	6.5	54
153	Epoxides and soluble epoxide hydrolase in cardiovascular physiology. *Physiological Reviews*, **2012**, 92, 101-30	47.9	261
152	11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. *American Journal of Physiology - Heart and Circulatory Physiology*, **2012**, 302, H1574-83	5.2	16
151	Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor ﬂagonist improve vascular function and decrease renal injury in hypertensive obese rats. *Experimental Biology and Medicine*, **2012**, 237, 1402-12	3.7	50
150	Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. *Kidney and Blood Pressure Research*, **2012**, 35, 595-607	3.1	23
149	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.. *FASEB Journal*, **2012**, 26, 686.4	0.9	
148	Novel Orally Active Epoxyeicosatrienoic Acid (EET) Analogs Attenuate Cisplatin Nephrotoxicity. *FASEB Journal*, **2012**, 26, 851.7	0.9	
147	Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. *Journal of Hypertension*, **2011**, 29, 1590-601	1.9	29
146	Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. *Journal of Physiology*, **2011**, 589, 207-19	3.9	31
145	Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. *American Journal of Hypertension*, **2011**, 24, 816-21	2.3	22

144	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2011**, 301, R1307-17	3.2	62
143	Cytochrome P450 eicosanoids and cerebral vascular function. *Expert Reviews in Molecular Medicine*, **2011**, 13, e7	6.7	55
142	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 9038-43	11.5	115
141	Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. *American Journal of Nephrology*, **2011**, 34, 268-80	4.6	41
140	Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2011**, 300, R1468-75	3.2	30
139	Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. *American Journal of Physiology - Renal Physiology*, **2011**, 301, F765-72	4.3	4
138	CYP Pathway Modulators Alter Development and Angiogenesis in Zebrafish Embryos. *FASEB Journal*, **2011**, 25, lb437	0.9	
137	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. *FASEB Journal*, **2011**, 25, 664.10	0.9	
136	Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. *Frontiers in Physiology*, **2010**, 1, 157	4.6	43
135	20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension. *Hypertension*, **2010**, 56, 822-3	8.5	2
134	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. *FASEB Journal*, **2010**, 24, 3770-81	0.9	116
133	Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. *American Journal of Physiology - Renal Physiology*, **2010**, 298, F86-94	4.3	39
132	Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. *PPAR Research*, **2010**, 2010, 703735	4.3	12
131	Epoxyeicosatrienoic acid analogs and vascular function. *Current Medicinal Chemistry*, **2010**, 17, 1181-90	4.3	85
130	Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. *Journal of Hypertension*, **2010**, 28, 582-93	1.9	18
129	Targeting epoxides for organ damage in hypertension. *Journal of Cardiovascular Pharmacology*, **2010**, 56, 329-35	3.1	49
128	Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. *Clinical Science*, **2010**, 118, 291-301	6.5	66
127	Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. *Clinical Science*, **2010**, 118, 617-32	6.5	37

126	Impaired mesenteric resistance artery relaxation to KATP channel activation in cardiometabolic syndrome is improved by rosiglitazone treatment. *FASEB Journal*, **2010**, 24, 978.9	0.9	
125	Soluble Epoxide Hydrolase Inhibition (SEHi) and Thiazolidinedione (TZD) in combination provide greater renal injury protection in Spontaneously Hypertensive Obese (SHROB) Rats.. *FASEB Journal*, **2010**, 24, 812.9	0.9	
124	Attenuated endothelin-1 (ET-1) vasoconstrictor responses in cardiometabolic syndrome are attributed to increased ET-B receptors. *FASEB Journal*, **2010**, 24, 978.10	0.9	
123	Vascular Endothelial Growth Factor (VEGF) Inhibitors Induce Hypertension, Afferent Arteriolar Dysfunction, and Glomerular Injury. *FASEB Journal*, **2010**, 24, 575.9	0.9	
122	The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension. *Pharmaceuticals*, **2009**, 2, 217-227	5.2	17
121	Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. *Nephron Physiology*, **2009**, 113, p23-8		21
120	Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. *American Journal of Physiology - Renal Physiology*, **2009**, 297, F740-8	4.3	109
119	Adenosine2A receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. *Hypertension*, **2009**, 54, 1223-5	8.5	2
118	Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. *European Journal of Pharmacology*, **2009**, 607, 143-50	5.3	36
117	Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nature Reviews Drug Discovery*, **2009**, 8, 794-805	64.1	458
116	Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. *Clinical and Experimental Pharmacology and Physiology*, **2009**, 36, 724-8	3	23
115	Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. *American Journal of Pathology*, **2009**, 174, 2086-95	5.8	93
114	Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. *Clinical Science*, **2009**, 116, 61-70	6.5	69
113	SPARC deficiency ameliorates renal damage resulting from angiotensin II and a high salt diet. *FASEB Journal*, **2009**, 23, 604.1	0.9	
112	Renal mechanisms of antihypertensive effects caused by inhibition of soluble epoxide hydrolase in Cyp1a1-Ren-2 transgenic rats.. *FASEB Journal*, **2009**, 23, 1016.4	0.9	
111	LC-MS measurement of the epoxyeicosatrienoic acid mimetic EET-8-ZE-D in rat serum. *FASEB Journal*, **2009**, 23, 1019.13	0.9	
110	Development of combined soluble epoxide hydrolase inhibitors and epoxide analogs with vasodilator activity. *FASEB Journal*, **2009**, 23, 766.2	0.9	
109	Epoxyeicosatrienoic acids (EET) contribute to flow-induced dilation in mice mesenteric resistance artery. *FASEB Journal*, **2009**, 23, 932.1	0.9	

108	SPARC ameliorates ovarian cancer-associated inflammation. *Neoplasia*, **2008**, 10, 1092-104	6.4	50
107	The Renal Microcirculation **2008**, 550-683		6
106	Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. *Journal of Biological Chemistry*, **2008**, 283, 24514-24	5.4	58
105	The Renal Microcirculation **2008**, 550-683		20
104	Increased blood pressure in mice lacking cytochrome P450 2J5. *FASEB Journal*, **2008**, 22, 4096-108	0.9	52
103	TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2008**, 294, R76-83	3.2	108
102	Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. *Hypertension*, **2008**, 51, 352-9	8.5	74
101	Eicosanoids and renal damage in cardiometabolic syndrome. *Expert Opinion on Drug Metabolism and Toxicology*, **2008**, 4, 165-74	5.5	46
100	Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. *Microcirculation*, **2008**, 15, 137-50	2.9	56
99	Soluble Epoxide Inhibition Differentially Modulates Flow Induced Vascular Remodeling in Spontaneously Hypertensive Stroke Prone Rats and Wistar Kyoto Rats. *FASEB Journal*, **2008**, 22, 479.42	0.9	
98	Soluble epoxide hydrolase inhibition attenuates the development of renovascular hypertension in 2K1C rats.. *FASEB Journal*, **2008**, 22, 479.7	0.9	
97	Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension. *FASEB Journal*, **2008**, 22, 947.8	0.9	
96	Soluble Epoxide Hydrolase Inhibition Modulates Gene Expression of Anti-Apoptotic and Apoptotic Factors. *FASEB Journal*, **2008**, 22, 733.11	0.9	1
95	Soluble epoxide hydrolase inhibitor improves cardiac ischemic tolerance in Ren-2 transgenic rats. *FASEB Journal*, **2008**, 22, 479.6	0.9	
94	The divergent role of epoxyeicosatrienoic acids in the regulation of renal function in normotensive and two-kidney one-clip Goldblatt hypertensive rats. *FASEB Journal*, **2008**, 22, 761.1	0.9	
93	Ether epoxyeicosatrienoic acid (EET) analogs lower blood pressure when administered in-vivo to the spontaneously hypertensive rats. *FASEB Journal*, **2008**, 22, 479.44	0.9	2
92	Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. *Vascular Pharmacology*, **2007**, 46, 144-51	5.9	12
91	Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. *Vascular Pharmacology*, **2007**, 47, 145-59	5.9	32

90	Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. *Prostaglandins and Other Lipid Mediators*, **2007**, 83, 50-61	3.7	41
89	Obesity, insulin resistance, and renal function. *Microcirculation*, **2007**, 14, 349-62	2.9	59
88	Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. *Kidney International*, **2007**, 72, 683-9	9.9	88
87	Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. *Hypertension*, **2007**, 50, 1069-76	8.5	62
86	Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. *Hypertension*, **2007**, 49, 893-901	8.5	38
85	Normalization of the ovarian cancer microenvironment by SPARC. *Molecular Cancer Research*, **2007**, 5, 1015-30	6.6	69
84	IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension. *Kidney and Blood Pressure Research*, **2007**, 30, 195-202	3.1	17
83	The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. *Kidney and Blood Pressure Research*, **2007**, 30, 335-46	3.1	9
82	Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. *American Journal of Pathology*, **2007**, 171, 1104-12	5.8	51
81	Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. *Journal of Clinical Investigation*, **2007**, 117, 2496-505	15.9	77
80	Dietary fat increases renal injury in SHR in the absence of changes in insulin sensitivity or blood pressure. *FASEB Journal*, **2007**, 21, A1194	0.9	
79	Rosaglitazone (RGZ) decreases renal damage in spontaneously diabetic Goto-Kakizaki (GK) rats. *FASEB Journal*, **2007**, 21, A1194	0.9	
78	Peroxisome proliferators-activated receptor-alpha activation increases renal CYP2C23 and decreases cyclin D1 and blood pressure in Zucker diabetic fatty rats. *FASEB Journal*, **2007**, 21, A842	0.9	
77	Long-term high fat diet treatment activates NF kappa B signaling and increases endothelial dysfunction in angiotensin II hypertensive rats. *FASEB Journal*, **2007**, 21, A1196	0.9	
76	High fat diet induces insulin resistance and heightened renal inflammation in angiotensin II hypertensive rats. *FASEB Journal*, **2007**, 21, A504	0.9	
75	PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 290, H2187-95	5.2	44
74	Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 290, H935-40	5.2	183
73	Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 290, R435-41	3.2	30

72	Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. *Hypertension*, **2006**, 47, 557-62	8.5	103
71	Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 318, 288-95	4.7	81
70	Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. *FASEB Journal*, **2006**, 20, 539-41	0.9	19
69	Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 318, 1307-14	4.7	38
68	Eicosanoids and renal vascular function in diseases. *Clinical Science*, **2006**, 111, 21-34	6.5	71
67	Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease. *Current Enzyme Inhibition*, **2006**, 2, 73-77	0.5	1
66	Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. *Cardiovascular Drug Reviews*, **2006**, 24, 169-88		78
65	Urea-based soluble epoxide hydrolase inhibitors dilate mesenteric resistance vessels. *FASEB Journal*, **2006**, 20, A669	0.9	1
64	Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. *FASEB Journal*, **2006**, 20,	0.9	3
63	CYP450, COX-2 and Obesity Related Renal Damage. *Toxicology Mechanisms and Methods*, **2005**, 15, 125-366		9
62	An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. *Journal of Cardiovascular Pharmacology*, **2005**, 46, 842-8	3.1	106
61	ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. *British Journal of Pharmacology*, **2005**, 146, 1019-26	8.6	81
60	Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2005**, 288, R188-96	3.2	64
59	An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. *Hypertension*, **2005**, 46, 975-81	8.5	205
58	Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. *American Journal of Physiology - Renal Physiology*, **2005**, 289, F760-7	4.3	24
57	L-type calcium channels in the renal microcirculatory response to endothelin. *American Journal of Physiology - Renal Physiology*, **2005**, 288, F771-7	4.3	26
56	Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. *Hypertension*, **2005**, 46, 562-8	8.5	36
55	Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. *Hypertension*, **2005**, 46, 366-71	8.5	34

54	Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. *American Journal of Physiology - Renal Physiology*, **2005**, 289, F496-503	4.3	183
53	Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. *Journal of Applied Physiology*, **2004**, 97, 1268-74	3.7	19
52	ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. *Hypertension*, **2004**, 43, 533-5	8.5	36
51	P2X receptor-stimulated calcium responses in preglomerular vascular smooth muscle cells involves 20-hydroxyeicosatetraenoic acid. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 1211-7	4.7	29
50	20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis?. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2004**, 287, R3-5	3.2	13
49	Renal autoregulation in P2X1 knockout mice. *Acta Physiologica Scandinavica*, **2004**, 181, 445-53		58
48	Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. *Obesity*, **2004**, 12, 1278-89		41
47	Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. *Journal of Hypertension*, **2004**, 22, 811-8	1.9	28
46	Rofecoxib decreases renal injury in obese Zucker rats. *Clinical Science*, **2004**, 107, 561-70	6.5	40
45	Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 1244-53	12.7	147
44	The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. *Peptides*, **2003**, 24, 1141-7	3.8	16
43	Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. *Hypertension*, **2003**, 42, 775-80	8.5	33
42	Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. *Hypertension*, **2003**, 41, 709-14	8.5	92
41	12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. *Journal of Lipid Research*, **2003**, 44, 2391-9	6.3	41
40	Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. *Hypertension*, **2003**, 42, 594-9	8.5	63
39	Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. *Journal of Clinical Investigation*, **2003**, 112, 1895-905	15.9	131
38	Renal AT1 receptor protein expression during the early stage of diabetes mellitus. *International Journal of Experimental Diabetes Research*, **2002**, 3, 97-108		36
37	Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. *Hypertension*, **2002**, 39, 116-21	8.5	137

36	Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. *Hypertension*, **2002**, 39, 690-4	8.5	345
35	Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. *American Journal of Physiology - Renal Physiology*, **2002**, 283, F415-22	4.3	41
34	Adaptations of the renal microcirculation to hypertension. *Microcirculation*, **2002**, 9, 315-28	2.9	9
33	Adaptations of the Renal Microcirculation to Hypertension. *Microcirculation*, **2002**, 9, 315-328	2.9	17
32	Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. *Journal of Vascular Research*, **2001**, 38, 247-55	1.9	104
31	Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 5211-6	11.5	207
30	The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2001**, 281, H2089-96	5.2	39
29	Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. *American Journal of Physiology - Renal Physiology*, **2001**, 280, F1054-61	4.3	39
28	Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. *Journal of Hypertension*, **2001**, 19, 983-92	1.9	52
27	Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. *Kidney International*, **2000**, 58, 2320-30	9.9	95
26	Postglomerular vasoconstriction to angiotensin II and norepinephrine depends on intracellular calcium release. *General Pharmacology*, **2000**, 34, 409-15		20
25	Epoxygenase metabolites. Epithelial and vascular actions. *Molecular Biotechnology*, **2000**, 16, 233-51	3	35
24	Eicosanoid regulation of the renal vasculature. *American Journal of Physiology - Renal Physiology*, **2000**, 279, F965-81	4.3	128
23	Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. *Hypertension*, **2000**, 35, 307-12	8.5	81
22	Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. *Hypertension*, **2000**, 35, 280-6	8.5	37
21	Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. *American Journal of Hypertension*, **2000**, 13, 810-8	2.3	40
20	ATP-mediated Ca2+ signaling in preglomerular smooth muscle cells. *American Journal of Physiology - Renal Physiology*, **1999**, 276, F450-6	4.3	13
19	Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors. *American Journal of Physiology - Renal Physiology*, **1999**, 277, F303-11	4.3	57

18	Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. *Hypertension*, **1999**, 33, 195-200	8.5	40
17	Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. *Hypertension*, **1999**, 33, 408-13	8.5	87
16	Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. *Hypertension*, **1999**, 34, 176-80	8.5	72
15	Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. *Hypertension*, **1999**, 34, 843-7	8.5	54
14	Neuronal nitric oxide synthase-dependent afferent arteriolar function in angiotensin II-induced hypertension. *Hypertension*, **1999**, 33, 462-6	8.5	25
13	Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. *British Journal of Pharmacology*, **1999**, 127, 1399-405	8.6	70
12	Heterogeneous activation mechanisms in the renal microvasculature. *Kidney International*, **1998**, 67, S17-21	5.9	25
11	Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. *American Journal of Hypertension*, **1998**, 11, 570-8	2.3	84
10	Interactive nitric oxide-angiotensin II influences on renal microcirculation in angiotensin II-induced hypertension. *Hypertension*, **1998**, 31, 1255-60	8.5	40
9	Calcium mobilization contributes to pressure-mediated afferent arteriolar vasoconstriction. *Hypertension*, **1998**, 31, 421-8	8.5	38
8	Neuronal nitric oxide synthase modulates rat renal microvascular function. *American Journal of Physiology - Renal Physiology*, **1998**, 274, F516-24	4.3	61
7	Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. *American Journal of Physiology - Renal Physiology*, **1998**, 275, F605-12	4.3	39
6	Unraveling the Mystery of Goldblatt Hypertension. *Physiology*, **1998**, 13, 170-176	9.8	50
5	Role of renal nerves in afferent arteriolar reactivity in angiotensin-induced hypertension. *Hypertension*, **1997**, 29, 442-9	8.5	46
4	Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca2+ from intracellular stores. *Hypertension*, **1997**, 29, 222-7	8.5	59
3	Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. *Hypertension*, **1996**, 27, 658-62	8.5	76
2	Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. *Hypertension*, **1996**, 28, 669-77	8.5	135
1	Identification of a putative microvascular oxygen sensor. *Circulation Research*, **1996**, 79, 54-61	15.7	137